AKT1 and non-small cell lung carcinoma: Meanwhile, the c-MET ligand HGF can also mediate resistance of NSCLC to gefitinib through the activation of the PI3K/AKT signaling pathway via GAB1 (Grb2 associated binder 1) (61).